Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet
Monte Rosa Therapeutics is rated a risky Buy, with valuation hinging on the clinical success and milestone payments from its outlicensed flagship asset MRT-6160. MRT-6160, targeting autoimmune diseases, offers differentiated safety and oral convenience, with Phase 2 results as the key near-term catalyst for GLUE. GLUE maintains a robust $626 million cash position, providing a 3.5-year runway and cushioning downside risk amid high clinical trial expenses.
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.15 per share a year ago.
Monte Rosa Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 105 | $1,307.89 | $1,062.6 | -$245.29 | -18.75% |
| NA Nizar Araji National Bank Of Canada /FI/ | 11 | $262.9 | $111.32 | -$151.58 | -57.66% |
| BG Bart Gancher Intech Investment Management LLC | 13,883 | $129,700.96 | $140,495.96 | $10,795 | 8.32% |
 John H. Burbank III Passport Capital LLC | 4.35M | $25.87M | $43.37M | $17.5M | 67.64% |
| CD Charlie Durham Sterling Capital Management LLC | 260 | $4,076.79 | $2,631.2 | -$1,445.59 | -35.46% |
Monte Rosa Therapeutics, Inc. (GLUE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Monte Rosa Therapeutics, Inc. ever had a stock split?
Monte Rosa Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Markus Warmuth CEO | NASDAQ (NGS) Exchange | 61225M102 CUSIP |
| US Country | 173 Employees | - Last Dividend | - Last Split | 24 Jun 2021 IPO Date |
Overview
Monte Rosa Therapeutics, Inc. is a pioneering clinical-stage biotechnology firm specializing in the creation of innovative small molecule precision medicines. Leveraging the body's natural protein degradation mechanisms, the company focuses on developing treatments for a variety of diseases by targeting proteins that are therapeutically relevant. Founded in 2019 and based in Boston, Massachusetts, Monte Rosa Therapeutics is at the forefront of biotechnological innovation, seeking to offer novel therapeutic options for various conditions by manipulating protein levels within the body.
Products and Services
- MRT-2359
- MRT-6160
- MRT-8102
- CDK2
An orally bioavailable molecular glue degrader designed to target the translation termination factor protein GSPT1. This product is aimed at treating MYC-driven tumors, offering a new approach in the battle against cancer by targeting the protein's influence on tumor growth and survival.
Developed for the treatment of systemic and central nervous system autoimmune diseases, MRT-6160 represents a significant advancement in the field of autoimmunity. Through its innovative mechanism, it targets specific pathways involved in autoimmune responses, offering potential relief for sufferers of these debilitating conditions.
Targeting IL-1/NLRP3 driven inflammatory diseases, MRT-8102 is a testament to Monte Rosa Therapeutics' commitment to combating inflammation through cutting-edge science. By focusing on the IL-1 and NLRP3 pathways, this product aims to provide effective treatment options for inflammatory diseases, highlighting the versatility of protein degradation technologies.
Specially developed to treat ovarian, uterine, and breast cancers, the CDK2 product line underscores the company's dedication to female health. Targeting the cyclin-dependent kinase 2 (CDK2) enzyme, which is often implicated in the proliferation of cancer cells, this treatment option holds the promise for significant advancements in the therapy of these prevalent cancers.
Contact Information
